WuXi Biologics and Sinorda Biomedicine, a biomedical company advancing treatments in the fields of tract diseases, tumor immunity, and autoimmune diseases, announced a strategic collaboration concerning Sinorda’s therapeutic candidate SND006 on January 29th, 2026. According to a company press release announcing the agreement, WuXi will provide clinical supply for SND006’s preclinical pharmacology studies.
SND006 is a novel bispecific antibody currently being investigated as a potential treatment for inflammatory bowel disease (IBD) and other autoimmune diseases. In vitro functional validation studies have been completed and the company plans to submit IND applications in both China and the United States in 2026.
“Over the past decade, we have accumulated experience across hundreds of projects in bispecific and multispecific antibodies, which have become one of our fastest‑growing areas,” said Dr. Chris Chen, CEO, WuXi Biologics, in the release. “We are pleased to accelerate the development and manufacturing of Sinorda Biomedicine’s innovative bispecific antibody SND006 through our integrated technology platforms and comprehensive capabilities. Looking ahead, we will continue accelerating and transforming biologics discovery, development and manufacturing to empower global partners and make innovative biologics more accessible and affordable for patients worldwide.”
“SND006 is a potentially best-in-class innovative bispecific antibody discovered and developed by Sinorda Biomedicine, with the potential to deliver breakthroughs in the treatment of gastrointestinal and multiple autoimmune diseases,” said Dr. Pingsheng Hu, Chairman and General Manager, Sinorda Biomedicine, in the release. “WuXi Biologics is a global leader in CRDMO services, offering truly end‑to‑end solutions underpinned by accumulated know-how, comprehensive technology platforms, and a strong track record—particularly in the development and manufacturing of bispecific antibodies. We believe this collaboration will accelerate the IND filings of our innovative biologics in China and worldwide, address unmet medical needs in autoimmune diseases, and ultimately bring safe and effective therapies to patients.”
According to the release, the companies plan to further expand the collaboration around other treatments in Sinorda’s pipeline at some point in the future. Financial terms of the collaboration were not disclosed in the press release.
